THOR-809: An IL-2 Engineered From an Expanded Genetic Alphabet for the Potential Treatment of Autoimmune Disorders

Marcos E. Milla; Carolina E. Caffaro; Lina Ma; Ingrid B. Joseph; David B. Chen; Taylor Ismaili; Kristine M. San Jose; Yelena Pavlova; Namit Singh; Lilia K. Koriazova; Hans R. Aerni; Michael J. Pena; Jerod L. Ptacin

INTRODUCTION
Dual Pharmacology of IL-2 is Mediated by mAb and βγ Receptor Sub-Types

RESULTS
Screening in Vivo Identified Multiple IL-2 Synthorins With Differential Ex Vivo Pharmacology

RESULTS
THOR-809 Induces Treg Activation and Biomarkers of Suppressive Function in NHP

RESULTS
THOR-809 Does Not Expand CD8+ T or NK Cells in NHP

RESULTS
THOR-809 Induces CD25+ Tregs in Total Blood Cells

REFERENCES